PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
May 1, 2006, 00:00
10.1016/S1098-3015(10)64685-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)64685-2/fulltext
Title :
PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64685-2&doi=10.1016/S1098-3015(10)64685-2
First page :
Section Title :
Open access? :
No
Section Order :
93